Hepatocellular Carcinoma

In one line

[1]

Overview and Definition

Hepatocellular carcinoma (HCC) is a primary malignant epithelial neoplasm of the hepatocyte. It is the most common primary liver cancer (approximately 75 to 85 percent of primary liver malignancies) and the dominant histological type worldwide; intrahepatic cholangiocarcinoma (10 to 15 percent) and combined hepatocellular-cholangiocarcinoma are far less common. [1]

The single most important concept is that HCC is, overwhelmingly, a disease of the cirrhotic liver: around 80 to 90 percent of HCCs arise in a liver already damaged by chronic injury and fibrosis. This means that (a) the patient is usually known to the clinician before the cancer declares itself — the basis for surveillance; (b) the functional reserve of the surrounding liver is as important to outcome and to treatment choice as the tumour itself — the basis for Child-Pugh, ALBI, and the future liver remnant (FLR) concept; and (c) prevention of cirrhosis is prevention of HCC — the basis for hepatitis B vaccination, antiviral therapy and lifestyle measures. [1]

[1]

Liver Anatomy — the foundation everything else rests on

Understanding HCC surveillance imaging, resection planning and TACE requires a firm grasp of hepatic anatomy. [1]

Dual blood supply

The liver has a unique dual blood supply: [1]

• Portal vein carries approximately 75 percent of incoming blood — nutrient-rich, partially deoxygenated venous blood from the gut, spleen and pancreas.
• Hepatic artery (a branch of the coeliac axis, via the common hepatic artery) carries approximately 25 percent of incoming blood — oxygenated systemic arterial blood. [1]

Despite contributing only a quarter of flow, the hepatic artery provides around 50 percent of the liver's oxygen requirement. Venous drainage is via the three hepatic veins (right, middle, left) into the inferior vena cava, which runs in a groove between the right and middle hepatic veins — the plane of the main portal scissure (Cantlie line) separating the right and left functional lobes. [1]

Why the dual supply matters in HCC — the "arterialisation" concept

This is a recurring exam point. Normal hepatic parenchyma is predominantly portal-venous fed; HCC is predominantly arterial fed. As a regenerative nodule transforms into a dysplastic nodule and then into HCC, there is a progressive loss of portal tracts and acquisition of abnormal arterial (neoangiogenic) supply, mainly from the hepatic artery. This single physiological change is exploited in three entirely different ways: [1]

1. Diagnosis — on multiphase CT/MRI the tumour takes up contrast during the arterial phase (brighter than liver) and then washes out in the portal venous/delayed phases (darker than liver) because it lacks a portal supply. This arterial hyperenhancement + washout signature is the non-invasive hallmark of HCC.
2. Locoregional treatment — TACE delivers chemotherapy directly into the tumour's arterial feeder and then embolises it, exploiting the fact that the tumour depends on arterial flow while the surviving liver is sustained by the portal vein.
3. Systemic therapy target — the angiogenic switch (driven by VEGF and FGF) makes HCC vulnerable to anti-VEGF agents (bevacizumab) and multi-kinase inhibitors (sorafenib, lenvatinib). [1]

Couinaud segmentation — the surgical map

The functional anatomy used for resection is the Couinaud classification, which divides the liver into eight independent segments, each with its own portal pedicle (portal venous branch, hepatic arterial branch, bile duct) and drained by a hepatic vein. Segments are numbered I to VIII in a clockwise pattern when viewed from below (the visceral surface), with segment I (the caudate lobe) sitting posteriorly, draped around the IVC, and segments II to VIII forming the bulk. [1]

[1]

Standard resections follow Couinaud anatomy: a right hepatectomy removes segments V to VIII; a left hepatectomy removes II to IV; an extended right hepatectomy (trisegmentectomy) removes IV to VIII; an extended left hepatectomy removes II to IV plus V and VIII; a left lateral sectionectomy removes II and III; and segmentectomies target individual segments. Each resection is defined by the portal and hepatic venous planes it crosses — which is why intra-operative ultrasound and a knowledge of segmental anatomy are indispensable. [1]

Epidemiology

HCC is the 6th most commonly diagnosed cancer and the 3rd leading cause of cancer-related death globally, responsible for over 800,000 deaths per year. Its incidence is dramatically uneven across the globe and tracks closely with the prevalence of its viral causes. [1]

HCC shows a striking male predominance (approximately 2 to 4:1), partly due to higher HBV carriage, alcohol intake, smoking prevalence and androgen-driven tumour promotion. Peak age is 50 to 70 years in low-HBV regions and younger (20 to 40 years) in high-HBV, high-aflatoxin regions of Africa — where HCC in young adults without cirrhosis is a recognised pattern. [1]

Risk Factors — the complete high-yield list

HCC risk factors divide into those that act through chronic liver injury and cirrhosis (the great majority) and a smaller group that is directly oncogenic, independent of cirrhosis. [1]

Hepatitis B virus (HBV) — the global number one

HBV is the single most common cause of HCC worldwide, responsible for over half of all cases. HBV increases HCC risk 15 to 20-fold. Several features make HBV unique among HCC risk factors: [1]

• HCC can develop in HBV carriers without cirrhosis — unlike HCV, where cirrhosis is almost always a prerequisite. This is why HBV carriers themselves qualify for surveillance (see below), not just cirrhotics.
• Direct oncogenesis by viral DNA integration — HBV DNA integrates randomly into the host genome, causing chromosomal instability, insertional mutagenesis and dysregulation of growth-control genes. This integration can occur decades before cancer appears, which is why antiviral therapy reduces but does not eliminate HCC risk.
• HBx protein — a viral regulatory protein that transactivates host genes, including those driving proliferation and inhibiting p53-mediated apoptosis.
• Aflatoxin synergy — co-exposure to dietary aflatoxin B1 multiplies (not just adds to) the HBV risk. [1]

Markers of highest HBV-related risk: high viral load (HBV DNA over 2000 IU/mL), HBeAg positivity, genotype C (in Asia), male sex, older age, family history of HCC, and African descent. [1]

Hepatitis C virus (HCV)

HCV causes HCC almost exclusively through cirrhosis — HCC without cirrhosis is rare. The risk rises steeply once cirrhosis has developed, at approximately 1 to 4 percent per year. Eradication of HCV with direct-acting antivirals (DAAs) achieves a sustained virological response (SVR) in over 95 percent of cases and substantially reduces but does not abolish HCC risk — residual risk persists in those with established cirrhosis, so surveillance continues even after SVR. [1]

Non-alcoholic fatty liver disease / NASH (MASLD/MASH)

This is the fastest-growing cause of HCC in the Western world, driven by the epidemics of obesity, type 2 diabetes and metabolic syndrome. Key teaching points: [1]

• HCC can rarely arise in NAFLD without advanced fibrosis, but the great majority occurs in NASH-cirrhosis.
• Diabetes and obesity are independent risk factors even after accounting for cirrhosis — hyperinsulinaemia, insulin-like growth factor signalling and chronic adipose-tissue inflammation (IL-6, TNF-alpha) provide the oncogenic drive.
• NASH-HCC patients are often diagnosed later, partly because they have been outside traditional surveillance pathways. [1]

Alcohol

Alcohol acts synergistically with viral hepatitis and metabolic risk factors to accelerate fibrosis toward cirrhosis. Alcohol-related cirrhosis carries an HCC risk of roughly 1 percent per year. Cessation reduces but does not eliminate risk once cirrhosis is established. [1]

Aflatoxin B1

A fungal toxin produced by Aspergillus flavus and Aspergillus parasiticus that contaminates stored grains (maize, groundnuts, rice) in hot, humid climates of sub-Saharan Africa and Southeast Asia. Aflatoxin is metabolised to a reactive epoxide that forms DNA adducts, producing a characteristic codon 249 (R249S) mutation in the TP53 tumour suppressor gene — a molecular signature of aflatoxin-driven HCC. The combination of aflatoxin plus HBV is among the most powerful carcinogenic synergies known, multiplying risk many-fold. [1]

Hereditary haemochromatosis

Cirrhosis from iron overload in untreated HFE (C282Y homozygous) haemochromatosis carries one of the highest per-cirrhosis HCC risks (up to 20 to 30 percent lifetime). Iron generates reactive oxygen species that damage DNA; HCC is a leading cause of death in untreated disease. Venesection (or iron chelation) before cirrhosis develops largely abolishes this risk. [1]

Other hereditary and metabolic causes

• Alpha-1 antitrypsin deficiency (ZZ phenotype) — cirrhosis and HCC.
• Hereditary tyrosinaemia type I — very high HCC risk in untreated children.
• Glycogen storage diseases (Ia, III).
• Porphyria cutanea tarda.
• Wilson disease — cirrhosis possible but HCC is relatively uncommon (protective effect of copper?). [1]

Other chronic liver diseases

Primary biliary cholangitis (PBC) (especially with advanced fibrosis), autoimmune hepatitis with cirrhosis, and haemophilia with transfusion-acquired HCV all carry elevated risk. Budd-Chiari syndrome with established cirrhosis also increases HCC risk. [1]

Behavioural and environmental factors

Tobacco smoking modestly increases risk and synergises with alcohol and viral hepatitis. Anabolic steroid and androgen use is linked to benign and malignant liver tumours. Betel quid chewing contributes in some populations. [1]

Pathophysiology and Molecular Biology

The multistep carcinogenesis model (the cirrhosis pathway)

The dominant pathogenetic sequence in cirrhosis is a stepwise progression from a regenerative nodule to a low-grade dysplastic nodule, then a high-grade dysplastic nodule with a focus of early HCC ("nodule-in-nodule"), and finally overt HCC — the so-called dysplasia-carcinoma sequence. Two structural changes accompany this histological march: [1]

1. Arterialisation — progressive loss of portal tracts and acquisition of abnormal arterial neoangiogenic supply (as described above), which is exactly what multiphase imaging detects.
2. Microvascular invasion — the propensity of HCC to invade portal or hepatic venous branches, producing intrahepatic satellite lesions and driving post-resection recurrence. [1]

Molecular pathways — the high-yield mutations

HCC is one of the most genetically heterogeneous of solid tumours, but a handful of recurrently altered driver pathways account for most cases. These are increasingly exam-relevant and underpin emerging targeted therapies. [1]

• TERT promoter mutation — the single most frequent driver mutation (roughly 60 percent of HCC). It reactivates telomerase, allowing unlimited replicative potential. TERT promoter mutations are often an early event, present even in dysplastic nodules.
• Wnt / beta-catenin pathway (CTNNB1) — activating mutations in beta-catenin (CTNNB1) (approximately 30 percent) or inactivation of its negative regulators (AXIN1, APC) stabilise beta-catenin, driving nuclear translocation and transcription of proliferative genes (cyclin D1, MYC). Wnt-activated HCCs are often well-differentiated, chemoresistant, and immune-cold (excluded from T-cell infiltration) — relevant to immunotherapy response.
• TP53 — inactivated by mutation in roughly 25 to 30 percent, especially in HBV- and aflatoxin-driven tumours. Aflatoxin produces the signature R249S "mutant" at codon 249. TP53-mutant tumours tend to be aggressive, poorly differentiated, and have a poor prognosis.
• Chromatin remodelling genes — ARID1A and ARID2 (SWI/SNF complex) are recurrently mutated; their loss impairs normal transcriptional regulation.
• PI3K/AKT/mTOR pathway — activating alterations in PIK3CA, loss of PTEN, or FGF19 amplification (a potential therapeutic target).
• NFE2L2 (NRF2) pathway — mutations that constitutively activate the antioxidant stress response, protecting tumour cells from oxidative damage and conferring chemoresistance. [1]

Host-tumour and immune factors

The tumour microenvironment of HCC is immunosuppressive, with abundant tumour-associated macrophages, regulatory T cells and checkpoint-ligand expression (PD-L1) — the biological rationale for checkpoint blockade (atezolizumab, anti-PD-L1) combined with anti-VEGF (bevacizumab, which also reverses VEGF-driven immunosuppression and improves drug delivery). [1]

[1]

Clinical Presentation

In a cirrhotic patient under surveillance, HCC is most often detected asymptomatically as a nodule on surveillance ultrasound. Symptomatic presentation implies advanced disease and portends a poor outcome. Recognised patterns include: [1]

• Abdominal pain (right upper quadrant), weight loss, anorexia, early satiety — the "mass effect" of a large tumour.
• Hepatomegaly with a hard, irregular, nodular edge; a palpable bruit over the liver is occasionally heard (tumour vascularity).
• Decompensation of known cirrhosis — new or worsening ascites, jaundice, or encephalopathy; sudden haemorrhagic ascites suggests tumour bleeding.
• Paraneoplastic syndromes — non-islet-cell tumour hypoglycaemia (insulin-like growth factor II), erythrocytosis (erythropoietin production), hypercalcaemia (parathyroid hormone-related peptide), diarrhoea, and dermatomyositis.
• Acute presentation — haemoperitoneum from tumour rupture (a surgical emergency seen particularly in large, superficial tumours, more common in HBV-related and Asian cohorts), or acute liver failure on chronic liver disease. [1]

Examination may reveal signs of chronic liver disease (palmar erythema, spider naevi, gynaecomastia, clubbing, Dupuytren contracture, ascites, caput medusae, asterixis) together with the tumour itself. A friction rub or bruit over the liver is a classic exam finding. [1]

Surveillance — who, when, and how

The aim of surveillance is to detect HCC at an early stage (BCLC 0/A) when curative treatment (resection, transplant, ablation) is still possible. Surveillance targets the at-risk population — it is not for the general public. [1]

Who should undergo surveillance?

The AASLD and EASL recommend 6-monthly liver ultrasound +/- serum AFP for: [1]

1. All patients with cirrhosis of any aetiology — Child-Pugh A, B, and selected C (those listed for transplant). The annual HCC incidence in cirrhosis is 1 to 8 percent, high enough to justify surveillance.
2. HBV carriers, even without cirrhosis, if any of:
   • Asian men over 40, Asian women over 50.
   • All persons of African descent over age 20 (higher risk at younger age).
   • Family history of HCC in a first-degree relative.
   • High HBV DNA (over 2000 IU/mL) with active hepatitis in patients over 40 (men) / 50 (women).
3. Non-cirrhotic NAFLD/NASH with advanced fibrosis (F3/F4).
4. Stage 4 primary biliary cholangitis (advanced fibrosis). [1]

Who does NOT benefit from surveillance?

• Child-Pugh C patients who are not transplant candidates — surveillance cannot alter outcome.
• HBV carriers below the age/sex thresholds without risk factors.
• HCV patients without cirrhosis after achieving SVR (low residual risk). [1]

How is surveillance performed?

• Liver ultrasound every 6 months. The 6-month interval reflects HCC's volume doubling time (a 1 cm tumour takes roughly 4 to 6 months to grow to 2 cm). Sensitivity for early-stage HCC is 60 to 80 percent, lower in obese patients, nodular cirrhosis and poor acoustic windows.
• Serum alpha-fetoprotein (AFP) — adds sensitivity when combined with ultrasound. A level over 400 ng/mL is highly suggestive of HCC, but AFP is neither sensitive nor specific enough to use alone (false positives in pregnancy, active hepatitis, germ-cell tumours; false negatives in well-differentiated small tumours). A rising trend is more meaningful than a single value.
• Any nodule over 1 cm detected on surveillance ultrasound must be characterised by multiphase CT or MRI (see LI-RADS).
• Emerging biomarkers — des-gamma-carboxyprothrombin (DCP, also PIVKA-II) and AFP-L3 (the Lens culinaris-agglutinin-reactive fraction of AFP) — improve sensitivity when combined with AFP, but are not yet universal. [1]

Diagnosis — the non-invasive paradigm

A fundamental shift in HCC diagnosis over the last two decades is that biopsy is usually not required in a cirrhotic liver. The EASL and AASLD endorse a non-invasive diagnosis: in a cirrhotic liver, a nodule over 1 cm showing the characteristic arterial phase hyperenhancement followed by portal venous or delayed phase washout on multiphase CT or MRI is diagnostic of HCC, without biopsy. [1]

The reasons are threefold: (1) imaging is highly specific in cirrhosis (the imaging signature reflects the pathophysiological arterialisation); (2) percutaneous biopsy carries a small (1 to 3 percent) risk of tumour seeding along the needle track; and (3) biopsy has sampling error. Biopsy is reserved for lesions with atypical imaging features, in non-cirrhotic livers, or when imaging is equivocal (LI-RADS LR-3/LR-4). [1]

Staging workup

Once HCC is diagnosed, staging determines treatment: [1]

• Multiphase CT of chest/abdomen/pelvis (or CT chest + MRI liver) to define tumour burden, vascular invasion (especially portal vein tumour thrombus) and extrahepatic spread (lung, bone, adrenal).
• MRI liver if CT is indeterminate or for problem-solving.
• Bone scan if bone pain or raised alkaline phosphatase (bone metastases are osteolytic, painful).
• AFP as a baseline tumour marker (and to guide ramucirumab eligibility later).
• Child-Pugh / ALBI score for liver function; performance status (ECOG); full blood count, coagulation, liver biochemistry, renal function, viral markers. [1]

LI-RADS — the imaging classification

The Liver Imaging Reporting and Data System (LI-RADS) is the standardised radiological algorithm (used by AASLD) that stratifies liver observations in at-risk patients by the probability of HCC, from LR-1 (definitely benign) to LR-5 (definitely HCC). Only LR-5 observations are considered diagnostic of HCC without biopsy. [1]

The five major features

LI-RADS applies to observations in patients at risk for HCC and assesses five major features: [1]

1. Nodule size (under 10 mm / 10 to 19 mm / 20 mm and over).
2. Arterial phase hyperenhancement — APHE (non-rim-like enhancement unequivocally greater than surrounding liver in the arterial phase).
3. Washout — reduction in enhancement from earlier to later phases, producing hypoenhancement.
4. Enhancing capsule — smooth, capsular rim of enhancement in the portal venous or delayed phase.
5. Threshold growth — size increase of a mass by at least 50 percent within 6 months, or a new 10 mm+ observation within 24 months. [1]

The LI-RADS categories

[1]

Staging Systems

No single staging system dominates HCC perfectly, because prognosis depends on three independent axes — tumour burden, liver function, and patient performance status — and treatment must respect all three. The BCLC system is the most widely used and the one that most directly links stage to treatment. [1]

Child-Pugh score — functional liver reserve

The Child-Pugh (Child-Turcotte-Pugh) score estimates hepatic reserve using five parameters and is fundamental to HCC decision-making. [1]

Interpretation:

• Child-Pugh A (5 to 6) — well-compensated; eligible for resection and all systemic therapy.
• Child-Pugh B (7 to 9) — significant functional impairment; resection hazardous; transplant or locoregional therapy preferred.
• Child-Pugh C (10 to 15) — decompensated; best supportive care or transplant only; high perioperative mortality. [1]

ALBI grade — an objective alternative

The ALBI (Albumin-Bilirubin) grade uses only bilirubin and albumin and is more objective and reproducible than Child-Pugh (which incorporates subjective ascites/encephalopathy grading). It stratifies HCC prognosis finely and is increasingly reported in trials. [1]

• ALBI 1: score under -2.60 — best prognosis.
• ALBI 2: score -2.60 to -1.39 — intermediate.
• ALBI 3: score over -1.39 — worst prognosis. [1]

Formula: ALBI score = (0.66 x log10 bilirubin in umol/L) + (-0.085 x albumin in g/L). [1]

MELD score

The Model for End-stage Liver Disease (MELD) score (bilirubin, INR, creatinine, sodium — MELD-Na) governs liver transplant allocation in most Western systems. HCC candidates within Milan criteria are awarded a MELD exception score to compete fairly, because HCC risk rises with waiting time. [1]

The BCLC Algorithm — staging and treatment in one

The Barcelona Clinic Liver Cancer (BCLC) system links tumour burden, liver function and performance status to a first-line treatment recommendation. It is the framework most examiners expect. [1]

The BCLC is a guideline, not a law: many centres (especially in Asia) treat beyond BCLC — for example resecting multinodular disease, or using TACE/systemic therapy across boundaries. The up-to-7 criteria (sum of tumour size in cm plus number of tumours under 7) and other expanded criteria also inform transplant decisions. [1]

Treatment — modality by modality

Curative-intent options (BCLC 0/A)

1. Surgical resection

Resection offers the best chance of cure in well-selected patients but is constrained by two questions: is the tumour resectable, and — crucially — is the liver resectable? [1]

Patient and tumour selection:

• Optimal: single HCC, no portal hypertension, Child-Pugh A, normal bilirubin (under 17 umol/L), platelets over 100, no clinically significant portal hypertension (HVPG under 10 mmHg, no varices).
• Non-cirrhotic HCC is the ideal candidate — no functional liver limitation, so large resections are tolerated.
• Future liver remnant (FLR) is the surgical linchpin: a minimum FLR of 40 percent is required in a cirrhotic liver (versus about 20 to 30 percent in a healthy liver). If FLR is inadequate, it is augmented by portal vein embolisation (PVE) of the diseased-side branch (inducing contralateral hypertrophy over 4 to 6 weeks) or ALPPS (Associating Liver Partition and Portal vein ligation for Staged hepatectomy — accelerates hypertrophy in 1 to 2 weeks). [1]

Technique:

• Anatomical resection follows Couinaud segments (right/left hepatectomy, extended resections, segmentectomy) — preferred for HCC because it removes the tumour together with its portal tributaries and potential intra-segmental satellite lesions.
• Non-anatomical (wedge) resection for small peripheral tumours.
• Pringle manoeuvre — intermittent clamping of the hepatoduodenal ligament (hepatic artery + portal vein together) to reduce blood loss during parenchymal transection.
• CUSA (Cavitron Ultrasonic Surgical Aspirator) or crush-clamp technique for precise parenchymal transection.
• Intra-operative ultrasound is essential — to map the tumour, its relationship to vascular structures, detect satellite lesions, and confirm margin. [1]

Outcomes and recurrence:

• 5-year survival 50 to 70 percent for single tumours without vascular invasion.
• Recurrence is the rule, not the exception — 50 to 70 percent at 5 years — arising from intrahepatic metastases (within 2 years) or multicentric de novo tumours (later) in the diseased liver.
• Perioperative mortality 2 to 5 percent in high-volume centres (higher in cirrhotics with portal hypertension). [1]

2. Liver transplantation

Transplantation is theoretically the ideal treatment: it removes the tumour and the underlying cirrhotic field (abolishing recurrence risk in the native liver). It is reserved for patients within transplant criteria with decompensated cirrhosis or tumours not amenable to resection. [1]

Milan criteria (Mazzaferro et al., 1996):[1]

• Single tumour under 5 cm, OR up to 3 tumours each under 3 cm.
• No macrovascular invasion (no portal/hepatic vein tumour thrombus).
• No extrahepatic spread.
• Within these criteria, 5-year survival is 70 to 80 percent, comparable to transplantation for non-malignant indications. [1]

UCSF expanded criteria (Yao et al., 2001):[2]

• Single tumour under 6.5 cm, OR up to 3 tumours with largest under 4.5 cm and total tumour diameter under 8 cm.
• Not universally adopted; outcomes in selected centres approach Milan results. [1]

Bridging and downstaging therapy while awaiting transplant:

• TACE, radiofrequency ablation (RFA), microwave ablation (MWA), TARE (Y-90 radioembolisation), or SBRT — used to control tumour progression during the waiting period and, in downstaging, to bring initially beyond-criteria tumours back within Milan before listing. [1]

Post-transplant outcomes and immunosuppression:

• 5-year survival 70 to 80 percent within Milan criteria; HCC recurrence 10 to 15 percent.
• mTOR inhibitors (sirolimus, everolimus) may reduce HCC recurrence and are preferred immunosuppressants in some protocols. [1]

3. Thermal ablation (RFA / MWA)

• Radiofrequency ablation (RFA) and microwave ablation (MWA) are first-line curative options for small tumours (under 2 to 3 cm), achieving complete necrosis in 90 percent of under-2 cm tumours — comparable to resection in this size range, especially when resection is contraindicated.
• Percutaneous ethanol injection (PEI) is now largely superseded by RFA/MWA but remains useful for small tumours in poor candidates and for cystic lesions.
• Best for: single tumour under 3 cm, Child-Pugh A to B, unresectable or transplant-bridge.
• 5-year survival 40 to 70 percent; recurrence rates similar to resection. [1]

Intermediate-stage treatment (BCLC B)

Transarterial chemoembolisation (TACE)

TACE is the first-line treatment for BCLC B (intermediate, multinodular) disease — unresectable, multifocal HCC without portal vein invasion and with preserved liver function (Child-Pugh A to B). [1]

Rationale: HCC is arterially fed while the surrounding liver is portal-fed — so delivering chemotherapy into the hepatic artery and then embolising it concentrates drug in the tumour and starves it of arterial blood, while sparing the parenchyma. [1]

Technique:

• Catheter is advanced (via femoral or radial arterial access) under fluoroscopy into the hepatic artery and selectively into the tumour-feeding branch.
• Delivery of chemotherapy (doxorubicin, cisplatin, or mitomycin C) — either emulsified in Lipiodol (an oily contrast medium that is selectively retained in HCC) or loaded onto drug-eluting beads (DEB-TACE) for slow, sustained release.
• Followed by embolisation of the feeding artery with gelatin sponge, particles, or beads. [1]

Indications: BCLC B (multinodular, unresectable, no vascular invasion, Child-Pugh A to B). [1]

Contraindications:

• Absolute: portal vein tumour thrombus (PVT) — the liver then depends entirely on arterial flow, so embolising it causes infarction; decompensated cirrhosis (Child-Pugh C); extensive bilobar disease; renal failure; encephalopathy.
• Relative: bilirubin over 2 to 3 mg/dL, significant ascites, hepatofugal flow. [1]

Complications: Post-embolisation syndrome (fever, abdominal pain, nausea — self-limiting, 1 to 3 days), liver abscess, hepatic failure, non-target embolisation (gallbladder, gut), contrast nephropathy. [1]

Outcomes: improves survival versus best supportive care in BCLC B (median survival 20 to 30 months, versus 16 months untreated). Repeat sessions may be given for residual/recurrent disease. [1]

Transarterial radioembolisation (TARE) — Y-90

Yttrium-90 microspheres deliver internal radiation directly into the tumour arterial bed. Unlike TACE, TARE can be used in portal vein thrombosis (a relative/absolute contraindication for TACE) because it causes minimal ischaemia, and produces less post-embolisation syndrome. Used for downstaging, BCLC B, and selected BCLC C patients. [1]

Locoregional options beyond curative

Stereotactic body radiotherapy (SBRT) is an emerging alternative for tumours unsuitable for ablation or surgery, delivering highly conformal high-dose radiation in a few fractions. [1]

Advanced-stage treatment (BCLC C) — systemic therapy

Systemic therapy is for advanced HCC (BCLC C): macrovascular invasion or extrahepatic spread, or progression after locoregional therapy, in patients with preserved liver function (Child-Pugh A, selected B7) and ECOG PS 0 to 2. [1]

First-line: Atezolizumab + Bevacizumab (IMbrave150)[4]

The combination of the anti-PD-L1 checkpoint inhibitor atezolizumab with the anti-VEGF monoclonal antibody bevacizumab is now the standard first-line therapy following the IMbrave150 trial, which demonstrated a median overall survival of 19.2 months versus 13.4 months for sorafenib (HR 0.66). [1]

• Dose: atezolizumab 1200 mg + bevacizumab 15 mg/kg IV every 3 weeks.
• Prerequisite: oesophago-gastro-duodenoscopy (OGD) to identify and treat untreated varices before starting therapy — bevacizumab carries a gastrointestinal bleeding risk.
• Contraindications: uncontrolled autoimmune disease, uncontrolled hypertension, recent haemorrhage or thrombosis, untreated varices.
• Adverse effects: hypertension, proteinuria, arterial thromboembolism, bleeding, immune-related adverse events (hepatitis, colitis, pneumonitis, endocrinopathies), infusion reactions. [1]

First-line alternatives: Sorafenib (SHARP) and Lenvatinib (REFLECT)

In patients unsuitable for atezo+bev, the oral multi-kinase inhibitors remain first-line. [1]

Sorafenib (SHARP trial, 2008):[5] the agent that established systemic therapy for HCC, targeting Raf/MEK/ERK, VEGFR, PDGFR.

• Dose: 400 mg twice daily.
• Median OS: 10.7 months versus 7.9 months for placebo.
• Adverse effects: hand-foot skin reaction, diarrhoea, hypertension, fatigue, alopecia, rash.

Lenvatinib (REFLECT trial, 2018):[6] targets VEGFR1 to 3, FGFR1 to 4, PDGFR, RET, KIT.

• Non-inferior to sorafenib (median OS 13.6 months), with somewhat higher response rates; first-line alternative.
• Preferred over sorafenib where the tumour burden or response matters; cannot be used if the patient has bile duct invasion or over 50 percent liver involvement.
• Adverse effects: hypertension, proteinuria, fatigue, weight loss, hand-foot reaction (less than sorafenib).

Second-line options

After progression on (or intolerance to) first-line TKI therapy, validated second-line agents exist — an important advance in HCC care: [1]

• Regorafenib (RESORCE trial):[7] for patients who tolerated sorafenib but progressed on it; dose 160 mg OD, 3 weeks on/1 week off; improved OS (10.6 versus 7.8 months).
• Cabozantinib (CELESTIAL trial):[8] multi-kinase inhibitor (MET, VEGFR2, AXL) for patients who received up to two prior lines including sorafenib; 60 mg OD; improved OS.
• Ramucirumab (REACH-2 trial):[9] monoclonal antibody against VEGFR2; the first biomarker-selected second-line therapy — indicated only for AFP over 400 ng/mL; 8 mg/kg IV every 2 weeks.
• Pembrolizumab (anti-PD-1): useful for MSI-high or TMB-high tumours; also considered after atezo+bev in selected patients.

[1]

BCLC D — end-stage (best supportive care)

For terminal-stage HCC (PS over 2, Child-Pugh C without transplant option), the goal is symptom control and dignity: [1]

• Pain — paracetamol (avoid in high doses if decompensated) then weak opioids, then strong opioids (morphine; avoid NSAIDs due to bleeding and renal risk; avoid prolonged paracetamol in liver failure).
• Ascites — spironolactone +/- furosemide; large-volume paracentesis with albumin replacement (6 to 8 g per litre removed).
• Encephalopathy — lactulose + rifaximin.
• Nutritional support; palliative care referral; psychological and spiritual support; advance care planning.
• Median survival under 3 months. [1]

Complications and their management

• Tumour rupture with haemoperitoneum — emergency. Resuscitation, then transarterial embolisation (TAE) to control bleeding, with definitive treatment (resection if feasible) once stabilised.
• Portal vein tumour thrombosis — worsens portal hypertension and prognosis; contraindicates TACE; may be treated with TARE (Y-90) or systemic therapy.
• Liver failure / decompensation — managed with standard liver-failure measures; exclude precipitants (infection, bleeding, sedatives).
• Cancer cachexia — nutritional support, megestrol; manage nausea.
• Bone metastases — analgesia, palliative radiotherapy, bisphosphonates/denosumab.
• Spontaneous bacterial peritonitis in the cirrhotic patient with ascites — diagnostic paracentesis, third-generation cephalosporin (e.g. cefotaxime). [1]

Follow-up and surveillance after treatment

After curative-intent treatment (resection, transplant, ablation):

• Contrast CT or MRI every 3 to 6 months for the first 2 years, then 6 to 12 monthly, plus AFP every 3 months — to detect recurrence (common after resection/ablation) or de novo tumours.
• Ongoing management of underlying liver disease (antiviral suppression for HBV/HCV, abstinence from alcohol, control of metabolic risk factors) — because recurrence is often multicentric. [1]

After TACE/TARE: imaging (mRECIST) at 4 to 6 weeks to assess response, then repeat as needed. [1]

On systemic therapy: CT every 8 to 12 weeks (mRECIST); monitor for adverse effects (blood pressure, proteinuria, thyroid function, hepatitis for checkpoint inhibitors). [1]

Prevention Programmes

Prevention is the most cost-effective intervention in HCC and operates at three levels. [1]

Primary prevention (preventing the cause)

• Universal HBV vaccination — the cornerstone. A 3-dose schedule (birth, 1 month, 6 months); Taiwan became the first country to implement universal infant HBV vaccination (1984), after which childhood HCC incidence fell by approximately 70 percent (Chang et al., 1997).[3] WHO recommends universal HBV vaccination globally; birth dose is critical to prevent perinatal transmission.
• Antiviral therapy for chronic HBV — entecavir 0.5 mg daily or tenofovir (TDF) 300 mg daily as first-line suppressive therapy; reduces HCC risk by roughly 70 percent (from a 5-year incidence of about 8 percent down to 2 to 3 percent). Risk is reduced but not abolished, because HBV DNA integration may have already occurred.
• HCV eradication — direct-acting antivirals (DAAs), e.g. sofosbuvir + velpatasvir for 12 weeks, achieve SVR in over 95 percent. Reduces HCC risk substantially in cirrhotics but does not eliminate it — surveillance continues after SVR.
• Alcohol cessation; weight management and metabolic risk control for NAFLD/NASH.
• Aflatoxin avoidance — improved grain storage (desiccation, fungicide use) in sub-Saharan Africa and Southeast Asia; food-safety legislation.

Secondary prevention (early detection)

• 6-monthly liver ultrasound +/- AFP in the at-risk population (see Surveillance) — detects HCC at a curative stage. [1]

Tertiary prevention (preventing recurrence)

• Antiviral therapy after resection/ablation to suppress HBV and reduce de novo multicentric recurrence. [1]

Differential Diagnosis

A liver lesion in a cirrhotic patient is HCC until proven otherwise, but the differential is broad: [1]

• Benign lesions: haemangioma (typical peripheral nodular discontinuous enhancement with centripetal fill-in), focal nodular hyperplasia (central scar), hepatic adenoma (oral contraceptive/anabolic steroid use), regenerative/dysplastic nodules, focal fat sparing, simple cyst.
• Malignant: intrahepatic cholangiocarcinoma (delayed enhancement, capsular retraction, ductal dilation, CA 19-9 elevated), combined hepatocellular-cholangiocarcinoma, metastases (hypovascular common — breast, lung, colon; hypervascular — neuroendocrine, renal, melanoma), lymphoma, angiosarcoma.
• Infective/inflammatory: pyogenic / amoebic liver abscess (fever, pain, aspirate), hydatid cyst (Echinococcus), hepatic tuberculosis. [1]

The imaging signature (arterial hyperenhancement + washout) plus the setting (cirrhosis) is what makes LI-RADS LR-5 specific. [1]

Exam Pearls

• HCC is the 6th most common cancer and 3rd leading cause of cancer death; over 80 percent arise in cirrhotic livers. HBV is the global number-one cause; NASH/MASLD is the fastest-growing in the West.
• Liver dual supply: portal vein ~75 percent, hepatic artery ~25 percent. HCC is arterial — the basis of arterial hyperenhancement, TACE and anti-VEGF therapy.
• Couinaud: 8 segments, segment I = caudate lobe (drains directly to IVC — hypertrophies in Budd-Chiari). Resections follow segmental anatomy.
• Surveillance = 6-monthly USS +/- AFP in all cirrhotics and high-risk HBV carriers (Asian male over 40, Asian female over 50, African over 20, family history). Any nodule over 1 cm gets multiphase CT/MRI.
• Diagnosis is non-invasive in cirrhosis: nodule over 1 cm with arterial hyperenhancement + portal/delayed washout = HCC (LI-RADS LR-5); biopsy not required (needle-track seeding risk).[4]
• Child-Pugh A required for resection and full-dose systemic therapy; no clinically significant portal hypertension (HVPG under 10, platelets over 100, no varices) and normal bilirubin are the resection sweet-spot. FLR at least 40 percent in cirrhosis (augment with PVE or ALPPS).
• Milan criteria: single tumour under 5 cm OR up to 3 tumours each under 3 cm, no vascular invasion, no extrahepatic spread; 5-year survival 70 to 80 percent.[1] UCSF: single under 6.5 cm, or 3 with largest under 4.5 cm and total under 8 cm.[2]
• BCLC: 0/A = resect/transplant/ablate; B = TACE (contraindicated by portal vein thrombosis, Child-Pugh C); C = systemic therapy; D = best supportive care.
• First-line systemic: atezolizumab 1200 mg + bevacizumab 15 mg/kg q3w (OS 19.2 months, IMbrave150); pre-treatment OGD mandatory.[4] Alternatives: sorafenib 400 mg BD (OS 10.7, SHARP) and lenvatinib (OS 13.6, REFLECT).[5][6]
• Second-line: regorafenib (RESORCE), cabozantinib (CELESTIAL), ramucirumab only if AFP over 400 (REACH-2).[7][8][9]
• Prevention: universal HBV vaccination cut Taiwan childhood HCC by ~70 percent; entecavir/tenofovir reduce HBV-HCC risk ~70 percent; DAAs cure HCV in over 95 percent.[3]

Exam application bank (NEET-PG / INICET)

One-line answer

Hepatocellular carcinoma (HCC) is the 6th most common cancer and 3rd leading cause of cancer death worldwide. Most cases arise in the setting of cirrhosis (HBV, HCV, alcohol, NASH). Surveillance: 6-monthly USS +/- AFP in at-risk patients. Diagnosis: non-invasive (LI-RADS) by typical arterial enhancement + portal venous washout on CT/MRI. BCLC staging guides treatment: resection (early), transplant (Milan criteria), TACE (intermediate), sorafenib/atezolizumab+bevacizumab (advanced).

Worked stems (answer without another resource)

Stem 1 — Classic presentation. Map symptoms to mechanism; name the first investigation and first treatment step with dose/route if drug therapy is standard. [1]

Stem 2 — Unstable / complicated. List red flags that force immediate resuscitation, theatre, ICU, antidote, or reperfusion — and what you do in the first 15 minutes. [1]

Stem 3 — Atypical group. Elderly, pregnancy, child, or immunocompromised: how presentation and thresholds change. [1]

Stem 4 — Differential trap. Name the three closest mimics and one discriminator for each. [1]

Stem 5 — Disposition. Who goes home with safety-netting, who is admitted, who needs HDU/ICU/theatre, and what follow-up is mandatory. [1]

Rapid viva checklist

1. Definition + classification
2. Pathophysiology chain
3. Bedside signs / criteria
4. Score with exact components (if any)
5. Emergency bundle
6. Definitive therapy with doses
7. Complications of disease and of treatment
8. Special populations
9. Guideline/trial name if classic
10. Three exam traps

Coverage self-check

If you cannot answer any stem above from this page alone, re-read the matching section — the page is intended to be self-sufficient for final-prof and NEET-PG/INICET questions on Hepatocellular Carcinoma.

[1]

References

1. [1]Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis N Engl J Med, 1996.PMID 8594428
2. [2]Yao FY, Ferrell L, Bassi NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival Hepatology, 2001.PMID 11391528
3. [3]Chang MH, Chen CJ, Lai MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group N Engl J Med, 1997.PMID 9197213
4. [4]Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma N Engl J Med, 2020.PMID 32402160
5. [5]Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma N Engl J Med, 2008.PMID 18650514
6. [6]Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial Lancet, 2018.PMID 29433850
7. [7]Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial Lancet, 2017.PMID 27932229
8. [8]Abou-Alfa GK, Meyer T, Cheng AL, et al. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma N Engl J Med, 2018.PMID 29972759
9. [9]Zhu AX, Kang YK, Yen CJ, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial Lancet Oncol, 2019.PMID 30665869